Navigation Links
Selexis SA to Present and Partner at the BIO-Europe 2013 Partnering Conference
Date:10/24/2013

Geneva, Switzerland (PRWEB) October 24, 2013

Selexis SA, a serial innovation company focused on drug discovery for lead identification and cell line development for scale-up and manufacturing of therapeutic protein drugs, announced today the Company’s president and CEO, Igor Fish, Ph.D., will present, “Selexis SURE CHO-Mplus™ Libraries: Custom Solutions for Improved Recombinant Protein Production” on Tuesday, November 5 at 4:45 PM at the BIO-Europe 2013 Partnering Conference being held November 4 – 6, at the Messe Wien Exhibition and Congress Center in Vienna, Austria. The Company will be also taking part in the pre-scheduled partnering meetings.

Presentation Abstract:
Stable, high-level production of recombinant proteins requires not only elevated transcription, but also cellular systems that can accommodate all of the protein folding, metabolic, secretory transport and post-translational processing requirements of any given protein. These requirements can vary significantly from protein to protein. Leveraging data from the completed SURE CHO-M Genome and Transciptome, Selexis has engineered the SURE CHO-Mplus libraries to address expression issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration. With these libraries, Selexis has been able to significantly boost expression over broad range of proteins, including large multimeric structural proteins and and difficult to express proteins.

Companies or individuals attending BIO-Europe can schedule meetings with Selexis (registration required) by visiting: http://www.ebdgroup.com/bioeurope/index.php

About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information:

# # #

Read the full story at http://www.prweb.com/releases/selexis_bio_europe/protiens_antibodies/prweb11264432.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Selexis SA Announces Publication in Metabolic Engineering of Data Demonstrating Improvement of Therapeutic Protein Secretion with Engineered CHO Cells
2. Selexis SA to Present and Partner at the BIO-Europe Spring
3. Selexis SA to Partner and Exhibit at BIO 2013
4. Selexis SA Launches SURE CHO-Mplus™ Libraries
5. Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering
6. Advancement in Biologic Protein Expression Webinar Hosted by Selexis SA
7. Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013
8. Targeted therapeutics for colon cancer to be presented at AACR meeting
9. NYU Langone experts present research, clinical advances at neurosurgeons meeting
10. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
11. Presidential Recognition Awards presented during the 2012 AIUM Annual Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... 05, 2016 , ... The 2016 Nike Soccer Camp will be directed by ... coaching staff. Together they bring their winning Vandals coaching philosophy to young athletes. Programs ... 5-13, and high school players. Session dates are as follows: , Youth Day Camp ...
(Date:5/5/2016)... ... 2016 , ... Talent Tech Labs (TTL) is pleased to announce ... National Nurses Week (May 6-12). Currently, HireNurses is a job listing and matching ... Talent Tech Lab Virtual Incubation program, they will dramatically expand the functionality and ease ...
(Date:5/5/2016)... Toledo, Ohio (PRWEB) , ... May 05, 2016 , ... ... Revenue Cycle. , Clark brings more than 15 years of experience within the ... comes from a successful career as the Director of Patient Financial Services at Spectrum ...
(Date:5/5/2016)... , ... May 05, 2016 , ... The Lung Institute will celebrate its ... a seminar at most clinic locations throughout the month of May. To date, the Lung ... “The rapid growth that we’ve seen is a testament to the success of this treatment ...
(Date:5/5/2016)... ... May 05, 2016 , ... T.E.N., a technology and ... May 3, at the 2016 ISE® Central Executive Forum and Awards Gala at ... Chief Security Officer of HMS, was selected as the Information Security Executive® of ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... May 5, 2016 ... addition of the  "Europe Thrombocythemia Market ...  report to their offering.  ... , ,The latest research Europe Thrombocythemia ... 2016, provides comprehensive insights into Thrombocythemia ...
(Date:5/4/2016)... York , May 4, 2016 ... Transparency Market Research entitled "Brain Computer Interface Market - Global ... - 2024," the  global brain computer interface (BCI) market  is ... 2024. The market is estimated to expand at a ... 2016 to 2024. A BCI device provides ...
(Date:5/4/2016)... , May 4, 2016 ... concluded a series of free workshops across ... global requirements for Good Distribution Practices (GDP). ... which ensures that products are consistently stored, transported and ... authorization (MA) or product specification. Only a few years ...
Breaking Medicine Technology: